Biodesix Inc. BDSX
Medical Specialities · IPO 2020 · data as of November 13, 2026
Biodesix Inc. (BDSX) is a healthcare company listed in the US with a market value of about $110M. In the twelve months to September 30, 2026 it had revenue of $105M and net income of -$27M, a net margin of -25.7%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 14% a year, a 5-year average ROIC of -56%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 83% below the current price.
About Biodesix
Biodesix is listed in the US and classified in medical specialities, IPO year 2020. Revenue went from $25M in 2019 to $88M in 2025, growth of about 23.8% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 259% over three years (dilution for shareholders). It spends 14% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $105M | $88M | $71M | $49M | $38M | $55M | $46M | $25M |
| Net income | -$27M | -$35M | -$43M | -$52M | -$65M | -$43M | -$65M | -$31M |
| Free cash flow | -$19M | -$24M | -$52M | -$46M | -$48M | -$30M | -$23M | -$23M |
| EPS (diluted) | $-2.70 | $-4.67 | $-6.64 | $-12.83 | $-31.06 | $-31.67 | $-129.87 | $-2544.70 |
| Net margin | -25.7% | -39.9% | -60.2% | -106.2% | -171.3% | -79.2% | -143.7% | -125.2% |
| ROIC | — | -30.2% | -31.5% | -46.6% | -69.5% | -103.3% | -26.2% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Biodesix stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 83% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Biodesix pay a dividend?
Not currently.
Is Biodesix a good stock to buy?
We do not give buy or sell advice. Biodesix scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.